BURKITT LYMPHOMA
Clinical trials for BURKITT LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new BURKITT LYMPHOMA trials appear
Sign up with your email to follow new studies for BURKITT LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New transplant drug combo shows promise for blood cancer patients
Disease control CompletedThis study tested a new way to prepare patients with blood cancers for a bone marrow transplant from a half-matched donor. Instead of using the standard drug cyclophosphamide after transplant, doctors replaced it with bendamustine to see if it was safer and still worked. About 50…
Matched conditions: BURKITT LYMPHOMA
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Disease control
Last updated May 17, 2026 05:37 UTC
-
Half-Matched donor transplants offer hope for blood cancer patients
Disease control CompletedThis study tested a stem cell transplant from half-matched (haploidentical) family donors for people with various blood cancers. The treatment used a reduced-intensity chemotherapy and radiation regimen to prepare the body for the transplant. The goal was to see how many patients…
Matched conditions: BURKITT LYMPHOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 17, 2026 05:36 UTC
-
New drug combo shows promise for blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the treatment works. This is an early-stage study, so results help gui…
Matched conditions: BURKITT LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
CAR-T therapy Follow-Up study finds no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various blood cancers like lymphoma and leukemia. The goal was to see if any new or late side effects appeared over time and how long the treatment's effects lasted. It was …
Matched conditions: BURKITT LYMPHOMA
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated May 06, 2026 16:02 UTC